The search for new DHFR inhibitors: a review of patents, January 2001 – February 2005

During the past 5 years, intense research activity has come from both private companies and academic institutions, aimed at the discovery of new, effective dihydrofolate reductase (DHFR) inhibitors. This important enzyme was discovered in the late 1950s, and, after nearly five decades, it still continues to draw the attention of researchers worldwide. Its low molecular weight makes it ideal as one of the main tools in molecular biology research: that is, in X-ray crystallography, NMR spectroscopy, kinetic measurements, and site-directed mutagenesis. This review will focus on the most recent developments published in the field, paying particular attention to promising DHFR inhibitors, their chemistry and biological evaluation, and to new chemical and pharmaceutical processes.

[1]  A. Rosowsky,et al.  Further studies on the interaction of nonpolyglutamatable aminopterin analogs with dihydrofolate reductase and the reduced folate carrier as determinants of in vitro antitumor activity. , 2003, Biochemical pharmacology.

[2]  R. Durand,et al.  Dihydrofolate reductase inhibitors: new developments in antiparasitic chemotherapy , 2001 .

[3]  A. Rosowsky,et al.  Efficient utilization of the reduced folate carrier in CCRF-CEM human leukemic lymphoblasts by the potent antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L- ornithine (PT523) and its B-ring analogues. , 2000, Biochemical pharmacology.

[4]  Amy C Anderson,et al.  Targeting DHFR in parasitic protozoa. , 2005, Drug discovery today.

[5]  T. Reese,et al.  In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives , 1999, NMR in biomedicine.

[6]  J. Åqvist,et al.  Design, synthesis, and computational affinity prediction of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[7]  R. Haynes,et al.  dUTP pyrophosphatase as a potential target for chemotherapeutic drug development. , 1997, Acta biochimica Polonica.

[8]  S. Queener,et al.  Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim. , 2002, Journal of medicinal chemistry.

[9]  S. P. Greatbanks,et al.  Computational Methods for the Study of Enzymic Reaction Mechanisms. 1. Application to the Hydride Transfer Step in the Catalysis of Dihydrofolate Reductase , 2002 .

[10]  G. Curt,et al.  Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. , 1985, The Journal of clinical investigation.

[11]  N Bodor,et al.  Soft drug design: General principles and recent applications , 2000, Medicinal research reviews.

[12]  H Schenone,et al.  [Special program for research and training in tropical diseases]. , 1998, Annales de la Societe belge de medecine tropicale.

[13]  Maria Paola Costi,et al.  Update on antifolate drugs targets. , 2001, Current drug targets.

[14]  C. Inderlied,et al.  New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity. , 2004, Journal of medicinal chemistry.

[15]  Interactions of 5-deazapteridine Derivatives with Mycobacterium tuberculosis and with Human Dihydrofolate Reductases , 2004, Journal of biomolecular structure & dynamics.

[16]  Robert C. Reynolds,et al.  Antimycobacterial Activities of 2,4-Diamino-5-Deazapteridine Derivatives and Effects on Mycobacterial Dihydrofolate Reductase , 2000, Antimicrobial Agents and Chemotherapy.

[17]  A. Smith,et al.  Genetic characterization of trimethoprim resistance in Haemophilus influenzae , 1996, Antimicrobial agents and chemotherapy.

[18]  A. Rosowsky,et al.  Synthesis and Potent Antifolate Activity and Cytotoxicity of B-Ring Deaza Analogues of the Nonpolyglutamatable Dihydrofolate Reductase Inhibitor Nα-(4-Amino-4-deoxypteroyl)-Nδ-hemiphthaloyl-l-ornithine (PT523) , 1998 .

[19]  S F Queener,et al.  Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii. , 2001, Journal of medicinal chemistry.

[20]  D. W. Fry,et al.  Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. , 1983, Cancer research.

[21]  P. Olliaro,et al.  Mode of action and mechanisms of resistance for antimalarial drugs. , 2001, Pharmacology & therapeutics.

[22]  James Inglese,et al.  gamma-Fluoromethotrexate: synthesis and biological activity of a potent inhibitor of dihydrofolate reductase with greatly diminished ability to form poly-gamma-glutamates. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Debabrata Banerjee,et al.  Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. , 2002, Biochimica et biophysica acta.

[24]  D E Snider,et al.  Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. , 1995, JAMA.

[25]  F. M. Huennekens In search of dihydrofolate reductase , 1996, Protein science : a publication of the Protein Society.

[26]  A. Rosowsky,et al.  Synthesis of the Folylpolyglutamate Synthetase Inhibitor Nα-Pteroyl-Lornithine and its Nδ-Benzoyl and Nδ-Hemiphthaloyl Derivatives, and an Improved Synthesis of Nα-( 4-Amino-4-deoxypteroy1)-Nδ-hemiphthaloyl-Lornithine , 1989 .

[27]  D. Crowther,et al.  Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Presant,et al.  Non‐invasive 19F‐NMRS of 5‐fluorouracil in pharmacokinetics and pharmacodynamic studies , 1998, NMR in biomedicine.

[29]  J. A. Donkersloot,et al.  A conservative amino acid mutation in the chromosome-encoded dihydrofolate reductase confers trimethoprim resistance in Streptococcus pneumoniae. , 1998, The Journal of infectious diseases.

[30]  R. Rappuoli,et al.  The impact of genomics on vaccine design. , 2005, Trends in biotechnology.

[31]  O. Santos-Filho,et al.  Type 2 antifolates in the chemotherapy of falciparum malaria , 2002 .

[32]  L F Kuyper,et al.  X-Ray crystal structures of Candida albicans dihydrofolate reductase: high resolution ternary complexes in which the dihydronicotinamide moiety of NADPH is displaced by an inhibitor. , 2001, Journal of medicinal chemistry.

[33]  A. Rosowsky,et al.  Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells. , 1995, Molecular pharmacology.

[34]  J. Bertino,et al.  Karnofsky memorial lecture. Ode to methotrexate. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Gready,et al.  Energetically most likely substrate and active-site protonation sites and pathways in the catalytic mechanism of dihydrofolate reductase. , 2001, Journal of the American Chemical Society.

[36]  A. Rosowsky,et al.  Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells. , 1994, Molecular pharmacology.

[37]  K Bowden,et al.  Structure-activity relationships of dihydrofolate reductase inhibitors. , 1993, Journal of chemotherapy.

[38]  G. Eliopoulos,et al.  Resistance to trimethoprim-sulfamethoxazole. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  J. Koutcher,et al.  A fluorine-labeled methotrexate as a probe for monitoring tumor antifolate pharmacokinetics: synthesis, in vitro cytotoxicity, and pilot in vivo 19F magnetic resonance spectra. , 2003, Molecular cancer therapeutics.

[40]  A. Rosowsky PT523 and other aminopterin analogs with a hemiphthaloyl-L-ornithine side chain: exceptionally tight-binding inhibitors of dihydrofolate reductase which are transported by the reduced folate carrier but cannot form polyglutamates. , 1999, Current medicinal chemistry.

[41]  Jeffrey M. Blaney,et al.  Structure-activity relationships of dihydrofolated reductase inhibitors , 1984 .

[42]  Yongyuth Yuthavong,et al.  Insights into antifolate resistance from malarial DHFR-TS structures , 2003, Nature Structural Biology.

[43]  R. Moran,et al.  Methotrexate analogues. 33. N delta-acyl-N alpha-(4-amino-4-deoxypteroyl)-L-ornithine derivatives: synthesis and in vitro antitumor activity. , 1988, Journal of medicinal chemistry.

[44]  Gerd Folkers,et al.  Molecular Modeling, Basic Principles and Applications , 1996 .

[45]  R. Reynolds,et al.  Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase. , 1998, The Journal of antimicrobial chemotherapy.

[46]  L. Amzel,et al.  Tuberculosis drug targets. , 2002, Current drug targets.

[47]  R. M. Hyde,et al.  2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 7. Analysis of the effect of 3,5-dialkyl substituent size and shape on binding to four different dihydrofolate reductase enzymes. , 1987, Journal of medicinal chemistry.

[48]  K. Keyomarsi,et al.  Synthesis and Biological Activity of Nω-Hemiphthaloyl-α,ω-diaminoalkanoic Acid Analogues of Aminopterin and 3′,5-Dichloroaminopterin , 1994 .

[49]  K. Rieckmann,et al.  Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials. , 2001, Journal of medicinal chemistry.

[50]  E. Brown,et al.  High throughput screening identifies novel inhibitors of Escherichia coli dihydrofolate reductase that are competitive with dihydrofolate. , 2003, Bioorganic & medicinal chemistry letters.

[51]  W G Hol,et al.  Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. , 2000, Journal of molecular biology.

[52]  S. Bushby,et al.  Trimethoprim, a sulphonamide potentiator. , 1968, British journal of pharmacology and chemotherapy.

[53]  M. Page,et al.  A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance. , 1997, Journal of molecular biology.

[54]  L. Kuyper,et al.  Selective inhibitors of Candida albicans dihydrofolate reductase: activity and selectivity of 5-(arylthio)-2,4-diaminoquinazolines. , 1995, Journal of medicinal chemistry.

[55]  R. Then,et al.  DNA and RNA synthesis: antifolates. , 2005, Chemical reviews.

[56]  J. Maddry,et al.  Antimycobacterial activity of 1-deaza-7,8-dihydropteridine derivatives against Mycobacterium tuberculosis and Mycobacterium avium complex in vitro. , 2001, The Journal of antimicrobial chemotherapy.